Exploiting the mTOR paradox for disease prevention

Oncotarget. 2012 Oct;3(10):1061-3. doi: 10.18632/oncotarget.712.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Intramural

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Neoplasms / prevention & control*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Antineoplastic Agents
  • MTOR protein, human
  • TOR Serine-Threonine Kinases